---
title: "Hansoh Pharma Wins NMPA Nod for Trial of New KRAS-Targeting Cancer Drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286266501.md"
description: "Hansoh Pharmaceutical Group has received approval from China's National Medical Products Administration to begin clinical trials of its innovative drug HS-10541, targeting KRAS G12C-mutated advanced solid tumors. This marks a significant milestone in the company's strategy to enhance its oncology portfolio and strengthen its position in China's competitive market. Analysts rate the stock (HK:3692) as a Buy with a price target of HK$47.00, reflecting confidence in the company's growth potential in the biopharmaceutical sector."
datetime: "2026-05-13T12:40:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286266501.md)
  - [en](https://longbridge.com/en/news/286266501.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286266501.md)
---

# Hansoh Pharma Wins NMPA Nod for Trial of New KRAS-Targeting Cancer Drug

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) just unveiled an update.

Hansoh Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of HS-10541 tablets, a self-developed Class 1 innovative drug. The therapy is designed for patients with KRAS G12C-mutated advanced solid tumors, underscoring the company’s strategic push into targeted oncology treatments.

The authorization marks a notable milestone in Hansoh’s innovation pipeline, potentially strengthening its competitive position in China’s high-value oncology market. Successful development of HS-10541 could enhance the group’s portfolio of advanced cancer therapies and reinforce its status as a leading domestic developer of innovative drugs.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

**More about Hansoh Pharmaceutical Group Company Limited**

Hansoh Pharmaceutical Group Company Limited is a China-based biopharmaceutical company focused on the research, development and commercialization of innovative medicines. The group develops its own Class 1 innovative drugs and targets unmet medical needs in areas such as oncology, where it aims to expand its presence in advanced solid tumor treatments.

**Average Trading Volume:** 9,518,902

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$221B

### Related Stocks

- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)

## Related News & Research

- [Hansoh Pharmaceutical Wins Breakthrough Therapy Status for Esophageal Cancer ADC](https://longbridge.com/en/news/285857826.md)
- [08:03 ETNCCN reafirma su compromiso con los recursos para el manejo del malestar relacionado con el cáncer](https://longbridge.com/en/news/287060831.md)
- [13:19 ETCancerCheck and Evexia Partner to Make Early, Accurate Cancer Detection a Reality](https://longbridge.com/en/news/286448727.md)
- [Nanjing Leads Biolabs Wins Phase III Green Light for Key Cancer Drug Opamtistomig](https://longbridge.com/en/news/286828874.md)
- [Avalere Health launches ‘Within Reach’, a new oncology anthology about what it really means to navigate cancer access, treatment, and care](https://longbridge.com/en/news/287075968.md)